Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3Hand-Foot Syndrome 2Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms, Male 2Rectal Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Cancer Related Fatigue 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 51Capecitabine 42Irinotecan 29Bevacizumab 21Radiotherapy 17Cetuximab 12Folfox protocol 11Chemoradiotherapy 11Neoadjuvant Therapy 10Chemotherapy, Adjuvant 9Surgical Procedures, Operative 6Drug Therapy 6XELOX 5Panitumumab 4Laparoscopy 4FOLFOXIRI protocol 4Transanal Endoscopic Microsurgery 3Radiation 3Octreotide 3IFL protocol 3Floxuridine 3Diathermy 3Celecoxib 3vatalanib 2spartalizumab 2Trinitrotoluene 2Tegafur 2Semaxinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Rectal Neoplasms × Pyridoxine × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡